IDEAL:  Incremental Decrease in End Points Through Aggressive Lipid Lowering

Principal researchers

Terje Pedersen (University of Oslo)

data custodian

Viatris Inc. (originally held by Pfizer Inc.)

funding

Pfizer Inc.

key publications 

• Design paper: Am J Cardiol 2004; 94: 720-724
• Main results: JAMA 2005; 294: 2437-2445
• Lipoprotein predictors: Ann Med 2008; 40: 456-64 (227)
• Safety:  Am J Cardiol 2009; 103(5); 577-82
• Preventing hospitalisation: Am J Cardiol 2009; 103: 1381-5 (229)
• Plasma triglycerides: Am J Cardiol 2009; 104: 459-63 (230) 
• Congestive heart failure: Atherosclerosis 2009; 205: 522-7 (231)
• Adherence-adjusted efficacy: Eur J Cardiovasc Prev Rehabil 2009; 16: 315-20 (232)
• Total cardiovascular disease burden: J Am Coll Cardiol 2009;54:2353-7
• Five year events: Am J Cardiol 2010; 106: 354-9 (234)
• CCR5 region: Circ Cardiovasc Genet 2010; 3: 162-8 (235)
• Chronic kidney disease: J Intern Med 2010; 267: 567-75 (236)
• Rheumatoid arthritis: Rheumatology 2011; 50(2): 324-9
• Impact of Smoking: Am J Cardiol 2011; 107: 145-50 (238)
• LDL cholesterol goals: Eur J Cardiovasc Prev Rehabil 2011; 18: 262-9 (239)
• Inflammatory joint disease: Arthritis Rheum 2012; 64: 2836-46 (240) 
• 719Arg variant of KIF6: Circ Cardiovasc Genet 2012; 5: 51-7 (241)
• Individualised prediction of treatment effect: Circulation 2013; 127: 2485-93 (242)
• New-onset diabetes: J Am Coll Cardiol 2013; 61: 148-52. Erratum in: J Am Coll Cardiol 2014; 64: 1970 (243)
• Effect in patients with mild-to-moderate baseline elevations in alanine aminostransferase levels. Internat J Cardiol 2013;168:3846-3852
• New-onset diabetes in TNT and IDEAL: J Am Coll Cardiol 2015; 65: 402-4 (245)